Navigation Links
Drug Company Reports Should be Read with Caution, Warn Doctors

A study published on today has found that reviews of drugs which are supported by the pharmaceutical industry are less transparent//, and are more likely to reach favourable conclusion on drugs, than independent reviews.

According to the authors, bias in drug trials is common and often favours the trial-sponsor’s product. To balance this effect, independent reviews – which can have a more critical and systematic approach - are essential to ensure doctors and other health professionals have the information they need on drugs.

The authors, based in Denmark, compared the results of 24 pairs of reviews conducted by different people on the same drugs. Compared to reviews supported by the pharmaceutical industry, reviews undertaken by the Cochrane Collaboration – an independent body – were of a higher quality and were more likely to address the potential for bias in the review.

Of seven industry-supported reviews, all recommended the experimental drug without reservation, whilst none of the corresponding Cochrane reviews reached the same conclusion. Six of the eight Cochrane reviews analysed had reservations about the quality or relevance of the trials or their findings and two of them noted that the effect decreased with increasing number of patients in the trial. Seven mentioned higher cost of the experimental drug as a problem. In contrast, none of the industry-supported reviews mentioned higher cost as a problem, and two claimed that the experimental drug was cost-effective.

The researchers also found that the reviews with not-for-profit support or no support had similarly cautious conclusions as the Cochrane reviews.

The authors conclude that industry-supported reviews should be read with caution. They also want greater transparency, including the inclusion of more information on methodology and the estimated effects of the drugs, in order to allow readers to judge the reliability of drug reviews.


Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Drug Company Admits Knowledge Of Side Effects In Monkeys
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. Indian Training Company To Train Children In Dubai, Sharjah
10. GE Healthcare to Acquire Swedish Medical Company
11. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology: